Jamison Private Wealth Management Inc. Purchases 39,471 Shares of Johnson & Johnson $JNJ

24 Dec 2025, 10:50 by Danessa Lincoln · The Markets Daily

Jamison Private Wealth Management Inc. raised its position in shares of Johnson & Johnson (NYSE:JNJ – Free Report) by 82.1% in the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 87,545 shares of the company’s stock after buying an additional 39,471 shares during the period. Johnson & Johnson comprises about 2.1% of Jamison Private Wealth Management Inc.’s holdings, making the stock its 8th largest holding. Jamison Private Wealth Management Inc.’s holdings in Johnson & Johnson were worth $16,233,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently modified their holdings of JNJ. Vanguard Group Inc. grew its position in Johnson & Johnson by 1.3% in the 2nd quarter. Vanguard Group Inc. now owns 237,047,859 shares of the company’s stock valued at $36,209,060,000 after acquiring an additional 3,085,180 shares in the last quarter. Geode Capital Management LLC grew its holdings in shares of Johnson & Johnson by 2.1% in the second quarter. Geode Capital Management LLC now owns 60,609,476 shares of the company’s stock valued at $9,227,988,000 after purchasing an additional 1,225,676 shares in the last quarter. Norges Bank acquired a new position in shares of Johnson & Johnson in the second quarter valued at approximately $4,877,174,000. Bank of New York Mellon Corp increased its stake in Johnson & Johnson by 2.7% during the 2nd quarter. Bank of New York Mellon Corp now owns 23,802,503 shares of the company’s stock worth $3,635,832,000 after buying an additional 620,039 shares during the period. Finally, Charles Schwab Investment Management Inc. lifted its holdings in Johnson & Johnson by 0.3% during the 2nd quarter. Charles Schwab Investment Management Inc. now owns 18,951,337 shares of the company’s stock worth $2,894,979,000 after buying an additional 52,074 shares in the last quarter. Hedge funds and other institutional investors own 69.55% of the company’s stock.

Johnson & Johnson Stock Performance

NYSE JNJ opened at $205.72 on Wednesday. The company has a fifty day moving average of $198.72 and a two-hundred day moving average of $180.11. The company has a market capitalization of $495.64 billion, a PE ratio of 19.86, a P/E/G ratio of 2.25 and a beta of 0.36. Johnson & Johnson has a 1 year low of $140.68 and a 1 year high of $215.18. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.07 and a quick ratio of 0.80.

Johnson & Johnson (NYSE:JNJ – Get Free Report) last posted its earnings results on Wednesday, August 30th. The company reported $2.26 earnings per share for the quarter. The business had revenue of $24.02 billion during the quarter. Johnson & Johnson had a return on equity of 32.73% and a net margin of 27.26%. As a group, analysts expect that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Tuesday, December 9th. Stockholders of record on Tuesday, November 25th were given a dividend of $1.30 per share. The ex-dividend date was Tuesday, November 25th. This represents a $5.20 dividend on an annualized basis and a dividend yield of 2.5%. Johnson & Johnson’s dividend payout ratio (DPR) is 50.19%.

Analyst Ratings Changes

A number of analysts have recently weighed in on the company. Raymond James Financial upped their price objective on Johnson & Johnson from $174.00 to $209.00 and gave the stock an “outperform” rating in a research report on Wednesday, October 15th. Argus set a $210.00 target price on Johnson & Johnson in a research note on Wednesday, October 15th. Barclays increased their price target on Johnson & Johnson from $176.00 to $197.00 and gave the company an “equal weight” rating in a research report on Tuesday, December 2nd. Bank of America lifted their price objective on Johnson & Johnson from $204.00 to $220.00 and gave the company a “neutral” rating in a research note on Monday, December 15th. Finally, Daiwa America upgraded shares of Johnson & Johnson from a “hold” rating to a “strong-buy” rating in a research note on Monday, October 20th. Four investment analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and nine have issued a Hold rating to the company. Based on data from MarketBeat.com, Johnson & Johnson has an average rating of “Moderate Buy” and a consensus target price of $210.25.

Check Out Our Latest Analysis on Johnson & Johnson

Johnson & Johnson News Roundup

Here are the key news stories impacting Johnson & Johnson this week:

Positive Sentiment: EU approval for Tremfya in pediatric plaque psoriasis expands J&J’s label for a high‑margin immunology drug and makes it the first IL‑23 inhibitor cleared for a pediatric indication — a potential sales tailwind. JNJ’s Tremfya Gets EU Approval for Pediatric Plaque Psoriasis
Positive Sentiment: FDA cleared a subcutaneous formulation of Rybrevant for NSCLC, improving patient convenience and potentially increasing uptake in oncology markets — helpful for medium‑term revenue growth. J&J Wins FDA Nod for Subcutaneous Version of NSCLC Drug Rybrevant (Revised)
Positive Sentiment: Analyst coverage is favorable: JNJ is being highlighted in high‑yield and defensive stock roundups for 2026, supporting demand from income and defensive investors. Top 5 High-Yield S&P 500 Stocks to Buy for Reliable Returns in 2026
Neutral Sentiment: Market attention is building ahead of J&J’s next quarterly earnings — analysts expect continued strength from new drug launches and pipeline momentum but legal overhang remains a wildcard. What to Expect From Johnson & Johnson’s Next Quarterly Earnings Report
Negative Sentiment: A Baltimore jury awarded roughly $1.5–1.56 billion to a plaintiff in a talc‑asbestos mesothelioma case — the largest single‑plaintiff talc award against J&J to date. The company says it will appeal, but the verdict re‑raises litigation risk, potential cash/outflow concerns and investor anxiety given tens of thousands of remaining talc suits. J&J vows appeal after US jury hits it with record $1.5 billion talc cancer award

Johnson & Johnson Profile

(Free Report)

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.

Featured Articles

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ – Free Report).